Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: Successes and hurdles

Current Opinion in Organ Transplantation

Volumn 20, Issue 1, 2015, Pages 72-78

  Introna, Martino ^a   Rambaldi, Alessandro ^a  

^a Unit of Nephrology and Dialysis   (Italy)

Author keywords

graft versus host disease; haematopoietic stem cell transplantation; mesenchymal stromal cells; platelet lysate

Indexed keywords

BONE MARROW CELL; CLINICAL TRIAL (TOPIC); GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; MESENCHYMAL STROMA CELL; NONHUMAN; REVIEW; ANIMAL; GRAFT VS HOST DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; PHYSIOLOGY;

ANIMALS; GRAFT VS HOST DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84921396543     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000158     Document Type: Review

References (60)

1. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graftversus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
2. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32:252-260.
3. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-Analysis of clinical trials. PLoS One 2012; 7:e47559.
4. Kaipe H, Erkers T, Sadeghi B, Ringden O. Stromal cells: are they really useful for GVHD?. Bone Marrow Transplant 2014; 49:737-743.
5. Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 2013; 92:1295-1308.
6. Galipeau J. The mesenchymal stromal cells dilemma: does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graftversus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013; 15:2-8.
7. Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versushost disease?. Biol Blood Marrow Transplant 2012; 18:822-840.
8. Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011; 13:262-268.
9. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
10. Remberger M, Ringden O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol 2012; 96:822-824.
11. Ball LM,BernardoME,Roelofs H, et al.Multiple infusions ofmesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013; 163:501-509.
12. Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014; 20:229-235.
13. Capelli C, Salvade A, Pedrini O, et al. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy 2009; 11:403-413.
14. Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014; 20:375-381.
15. von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2008; 43:245-251.
16. Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versushost disease. Biol Blood Marrow Transplant 2014; 20:1580-1585.
17. Wu Y, Wang Z, Cao Y, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. Ann Hematol 2013; 92:1675-1684.
18. Lee SH, Lee MW, Yoo KH, et al. Co-Transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant 2013; 48:1040-1045.
19. Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease: a phase II study. Stem Cells Int 2012; 2012:968213.
20. Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 2011; 20:1679-1685.
21. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-Tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16:838-847.
22. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009; 11:278-288.
23. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22:593-599.
24. Bernardo ME, Ball LM, Cometa AM, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-Threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2010; 46:200-207.
25. Vicente D, Podesta M, Pitto A, et al. Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality. Bone Marrow Transplant 2006; 38:111-117.
26. Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014; 124:354-362.
27. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-To-bedside update. Blood 2014; 124:363-373.
28. Alousi AM, Bolanos-Meade J, Lee SJ. Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant 2012; 19 (1 Suppl):S102-S108.
29. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12:443-458.
30. Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158:30-45.
31. Stenger EO, Turnquist HR, Mapara MY, Thomson AW. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012; 119:5088-5103.
32. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16:1504-1518.
33. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115:5412-5417.
34. Wolf D, von Lilienfeld-Toal M, Wolf AM, et al. Novel treatment concepts for graft-versus-host disease. Blood 2012; 119:16-25.
35. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110:3499-3506.
36. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262:509-525.
37. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726-736.
38. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28:1446-1455.
39. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012;10:709-716.
40. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3:e1886.
41. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
42. Ito T, Itakura S, Todorov I, et al. Mesenchymal stem cell and islet cotransplantation promotes graft revascularization and function. Transplantation 2010; 89:1438-1445.
43. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
44. Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12:2373-2383.
45. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755-1761.
46. Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61:219-227.
47. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 2013; 18:51-58.
48. Griffin MD, Ryan AE, Alagesan S, et al. Antidonor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013; 91:40-51.
49. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-555.
50. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013; 13:392-402.
51. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012; 119:1801-1809.
52. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010; 5:e10088.
53. NemethK, Leelahavanichkul A,YuenPS, et al.Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15:42-49.
54. Choi H, Lee RH, Bazhanov N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011; 118:330-338.
55. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2:141-150.
56. Li W, Ren G, Huang Y, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19:1505-1513.
57. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369:529-539.
58. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119:3854-3860.
59. Lucchini G, Introna M, Dander E, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010; 16:1293-1301.
60. Dander E, Lucchini G, Vinci P, et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26:1681-1684.